Related references
Note: Only part of the references are listed.IL-33 Promotes Gastric Cancer Cell Invasion and Migration Via ST2-ERK1/2 Pathway
Xi-Xiang Yu et al.
DIGESTIVE DISEASES AND SCIENCES (2015)
IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms
Lukas F. Mager et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells
Ivan P. Jovanovic et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Serum IL-33 as a Diagnostic and Prognostic Marker in Nonsmall Cell Lung Cancer
Liang-An Hu et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2013)
HIGH SERUM LEVELS OF THE INTERLEUKIN 33 RECEPTOR SOLUBLE ST2 AS A NEGATIVE PROGNOSTIC FACTOR IN HEPATOCELLULAR CARCINOMA
D. Bergis et al.
JOURNAL OF HEPATOLOGY (2013)
IL-33 attenuates EAE by suppressing IL-17 and IFN-γ production and inducing alternatively activated macrophages
Hui-Rong Jiang et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2012)
Expression of Tumor-Derived Vascular Endothelial Growth Factor and Its Receptors Is Associated With Outcome in Early Squamous Cell Carcinoma of the Lung
Maria J. Pajares et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
IL-33/ST2 axis in innate and acquired immunity to tumors
Ivan P. Jovanovic et al.
ONCOIMMUNOLOGY (2012)
ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma
Ivan Jovanovic et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
Basic Research in Kidney Cancer
Egbert Oosterwijk et al.
EUROPEAN UROLOGY (2011)
Prognostic Factors and Predictive Models in Renal Cell Carcinoma: A Contemporary Review
Maxine Sun et al.
EUROPEAN UROLOGY (2011)
The Epidemiology of Renal Cell Carcinoma
Borje Ljungberg et al.
EUROPEAN UROLOGY (2011)
Role of IL-33 in inflammation and disease
Ashley M. Miller
JOURNAL OF INFLAMMATION-LONDON (2011)
The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM
Stephen B. Edge et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Interleukin-33 contributes to both M1 and M2 chemokine marker expression in human macrophages
Amrita D. Joshi et al.
BMC IMMUNOLOGY (2010)
Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production
Yeon-Sook Choi et al.
BLOOD (2009)
Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review
Kiran Gupta et al.
CANCER TREATMENT REVIEWS (2008)
The IL-33/ST2 pathway: therapeutic target and novel biomarker
Rahul Kakkar et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
The IL-1-Like Cytokine IL-33 Is Constitutively Expressed in the Nucleus of Endothelial Cells and Epithelial Cells In Vivo: A Novel 'Alarmin'?
Christine Moussion et al.
PLOS ONE (2008)
Nuclear factor-κB in cancer development and progression
Michael Karin
NATURE (2006)
IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines
J Schmitz et al.
IMMUNITY (2005)
Multicenter determination of optimal interobserver agreement using the Fuhrman grading system for renal cell carcinoma -: Assessment of 241 patients with > 15-year follow-up
H Lang et al.
CANCER (2005)
Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma
A Zisman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score
I Frank et al.
JOURNAL OF UROLOGY (2002)
Share Paper
